|
Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bayer (Inst); Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - MDGN |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio |
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech |
Other Relationship - American Cancer Society; UpToDate |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma |
Research Funding - Prometheus (Inst) |
|
Bradley Alexander McGregor |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Genentech/Roche; Nextar; Seattle Genetics/Astellas |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer |
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Consulting or Advisory Role - Exelixis |
Speakers' Bureau - The France Foundation |
Travel, Accommodations, Expenses - Exelixis |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb |
|
|
Research Funding - Roche/Genentech; X4 Pharma |
|
|
Consulting or Advisory Role - Amgen; Castle Biosciences; Eisai; Exelixis; Novartis; Roche/Genentech |
Travel, Accommodations, Expenses - Newlink Genetics |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Fluiigm |
Other Relationship - Integrated DNA Technologies |
|
|
Stock and Other Ownership Interests - Neon Therapeutics; Neon Therapeutics (I) |
Consulting or Advisory Role - Neon Therapeutics; Neon Therapeutics (I) |
Patents, Royalties, Other Intellectual Property - Neon Therapeutics, Advisory Board Member; Neon Therapeutics, Advisory Board Member (I) |
|
|
Stock and Other Ownership Interests - Genome Medical; Syapse; Tango Therapeutics |
Consulting or Advisory Role - Genome Medical; InVitae; Novartis; Roche; Syapse; Takeda; Third Rock Ventures |
Speakers' Bureau - Illumina |
Research Funding - Bristol-Myers Squibb; Novartis |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Salus Discovery |
Consulting or Advisory Role - Sanofi; Sanofi |
Research Funding - Agensys (Inst); Medivation (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available. |
|
|
Employment - Dana-Farber Cancer Institute |
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis |
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst) |
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
Other Relationship - Bristol-Myers Squibb; Genentech/Roche |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Ipsen; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech |
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |
|
Lauren Christine Harshman |
Consulting or Advisory Role - Bayer; Corvus Pharmaceuticals; Exelixis; Genentech; KEW; Medivation/Astellas; Merck; Pfizer; Theragene |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Bayer |